Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Pertuzumab“
Suchtreffer
Begriffe & Kennungen
Enhertu · 4.8 · Enhertu 5.4 mg/kg in combination with pertuzumab
Eintrag öffnenEnhertu · 4.8 · Enhertu 5.4 mg/kg in combination with pertuzumab In patients treated with Enhertu 5.4 mg/kg in combination wit
Eintrag öffnenEnhertu · 4.8 · Enhertu 5.4 mg/kg in combination with pertuzumab In patients treated with Enhertu 5.4 mg/kg in combination wit
Eintrag öffnenEnhertu · 4.8 · Enhertu 5.4 mg/kg in combination with pertuzumab In patients treated with Enhertu 5.4 mg/kg in combination wit
Eintrag öffnenEnhertu · 4.8 · Enhertu 5.4 mg/kg in combination with pertuzumab In patients treated with Enhertu 5.4 mg/kg in combination wit
Eintrag öffnenEnhertu · 4.8 · Enhertu 5.4 mg/kg in combination with pertuzumab In patients treated with Enhertu 5.4 mg/kg in combination wit
Eintrag öffnenPerjeta · 4.5 · Five studies evaluated the effects of pertuzumab on the PK of co-administered cytotoxic agents, docetaxel, pac
Eintrag öffnenPerjeta · 4.5 · No pharmacokinetic (PK) interactions were observed between pertuzumab and trastuzumab, or between pertuzumab a
Eintrag öffnenPhesgo · 4.5 · 8 any PK interaction between pertuzumab and any of these agents. The PK of pertuzumab in these studies was com
Eintrag öffnenPhesgo · 4.5 · Five studies evaluated the effects of pertuzumab on the PK of co-administered cytotoxic agents, docetaxel, pac
Eintrag öffnenPhesgo · 4.5 · No PK interactions were observed between pertuzumab and trastuzumab, or between pertuzumab and docetaxel in a
Eintrag öffnenPhesgo · 4.5 · Pertuzumab
Eintrag öffnenPhesgo · 4.8 · 17 Pertuzumab intravenous in combination with trastuzumab and chemotherapy
Eintrag öffnenPhesgo · 4.8 · 18 neoadjuvant pertuzumab, trastuzumab and docetaxel experienced febrile neutropenia compared with 4 % of Asia
Eintrag öffnenPhesgo · 4.8 · 19 Pertuzumab intravenous in combination with trastuzumab and chemotherapy
Eintrag öffnenPhesgo · 4.8 · 20 The incidence of treatment-emergent anti-pertuzumab, anti-trastuzumab, and anti-vorhyaluronidase alfa antib
Eintrag öffnenPhesgo · 4.8 · As with all therapeutic proteins, there is the potential for an immune response to pertuzumab and trastuzumab
Eintrag öffnenPhesgo · 4.8 · During the neoadjuvant phase, 0.4 % of Phesgo treated patients and 0.4 % of intravenous pertuzumab and trastuz
Eintrag öffnenPhesgo · 4.8 · However, in the pivotal pertuzumab clinical trials with intravenous pertuzumab in combination with trastuzumab
Eintrag öffnenPhesgo · 4.8 · In neoadjuvant and adjuvant trials, pertuzumab was administered on the same day as the other study treatment.
Eintrag öffnen